Lauren Riker
Known title: Senior Vice President, FinanceCIK: 0001545439
Associated companies
Transaction History
| PCRX | ▲ Buy | Option Exercise | 6,000 | $194K | 10/8/2026 | View on chart |
| PCRX | ▼ Sell | Open Market | 6,000 | $218K | 10/8/2026 | View on chart |
| PCRX | ▼ Sell | Open Market | 6,115 | $144K | 6/11/2026 | View on chart |
| PCRX | ▼ Sell | Tax Withholding | 3,187 | $71K | 6/3/2026 | View on chart |
| PCRX | ▲ Buy | Grant | 19,273 | $0 | 2/11/2026 | View on chart |
| PCRX | ▼ Sell | Open Market | 4,000 | $83K | 2/2/2026 | View on chart |
| PCRX | ▼ Sell | Tax Withholding | 2,751 | $57K | 1/30/2026 | View on chart |
| PCRX | ▼ Sell | Open Market | 1,416 | $34K | 1/5/2026 | View on chart |
| PCRX | ▼ Sell | Tax Withholding | 159 | $4K | 1/2/2026 | View on chart |
| PCRX | ▼ Sell | Open Market | 5,578 | $146K | 6/4/2025 | View on chart |
| PCRX | ▼ Sell | Tax Withholding | 3,374 | $89K | 6/3/2025 | View on chart |
| PCRX | ▲ Buy | Grant | 30,600 | $0 | 2/1/2025 | View on chart |
| PCRX | ▼ Sell | Tax Withholding | 159 | $3K | 1/2/2025 | View on chart |
| PCRX | ▲ Buy | Grant | 21,360 | $0 | 6/12/2024 | View on chart |
| PCRX | ▼ Sell | Open Market | 3,970 | $114K | 6/12/2024 | View on chart |
| PCRX | ▼ Sell | Tax Withholding | 1,843 | $57K | 6/3/2024 | View on chart |
| PCRX | ▼ Sell | Tax Withholding | 159 | $5K | 1/2/2024 | View on chart |
| PCRX | ▼ Sell | Open Market | 643 | $25K | 7/5/2023 | View on chart |
| PCRX | ▲ Buy | Grant | 10,000 | $0 | 6/14/2023 | View on chart |
| PCRX | ▼ Sell | Open Market | 5,773 | $222K | 6/14/2023 | View on chart |
| PCRX | ▼ Sell | Open Market | 7 | $273 | 6/14/2023 | View on chart |
| PCRX | ▼ Sell | Open Market | 586 | $22K | 6/14/2023 | View on chart |
| PCRX | ▼ Sell | Open Market | 616 | $23K | 6/7/2023 | View on chart |
| PCRX | ▼ Sell | Open Market | 591 | $23K | 6/6/2023 | View on chart |
| PCRX | ▲ Buy | Grant | 5,850 | $0 | 6/8/2022 | View on chart |
| PCRX | ▼ Sell | Open Market | 1,150 | $71K | 6/6/2022 | View on chart |
| PCRX | ▲ Buy | Option Exercise | 9,300 | $101K | 3/10/2022 | View on chart |
| PCRX | ▼ Sell | Open Market | 8,400 | $598K | 3/10/2022 | View on chart |
| PCRX | ▼ Sell | Open Market | 900 | $65K | 3/10/2022 | View on chart |
| PCRX | ▲ Buy | Option Exercise | 2,500 | $27K | 1/18/2022 | View on chart |
| PCRX | ▼ Sell | Open Market | 2,500 | $162K | 1/18/2022 | View on chart |
| PCRX | ▲ Buy | Grant | 2,000 | $0 | 1/4/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Viatris agrees to acquire Pacira BioSciences for $1.65 billion
Viatris has announced plans to acquire Pacira BioSciences for $1.65 billion to expand its non-opioid pain management portfolio. Analysts from RBC and Truist have responded by raising their price targets to $36.50, though Truist downgraded the stock to Hold. The deal is seen as a significant move for Viatris, with RBC noting that a superior bid is unlikely.
Viatris agrees to acquire Pacira BioSciences for $1.65 billion. Viatris has announced plans to acquire Pacira BioSciences for $1.65 billion to expand its non-opioid pain management portfolio. Analysts from RBC and Truist have responded by raising their price targets to $36.50, though Truist downgraded the stock to Hold. The deal is seen as a significant move for Viatris, with RBC noting that a superior bid is unlikely.